Analysis Of Income And Expense [Abstract]

ABIVAX - Filing #2810976

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense	—	103 176 EUR	—	—	—	—	—	—	—	—	48 295 EUR	—	—	—	—	47 781 EUR
Finance income (cost)	—	20 364 EUR	—	—	—	—	—	—	—	—	4 096 EUR	—	—	—	—	1 052 EUR
Selling, general and administrative expense [abstract]
General and administrative expense	—	22 390 EUR	—	—	—	—	—	—	—	—	7 492 EUR	—	—	—	—	5 580 EUR
Revenue and other operating income	—	4 621 EUR	—	—	—	—	—	—	—	—	4 583 EUR	—	—	—	—	11 961 EUR
Operating expense	—	131 997 EUR	—	—	—	—	—	—	—	—	69 419 EUR	—	—	—	—	53 361 EUR
Sales and marketing expense	—	6 431 EUR	—	—	—	—	—	—	—	—	— EUR	—	—	—	—	— EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	112,000 EUR	—	—	—	—	—	—	—	—	— EUR	—	—	—	—	— EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	— EUR	147 516 EUR	147 740 EUR	— EUR	112,000 EUR	147 516 EUR	112,000 EUR	235,000 EUR	— EUR	60 740 EUR	60 506 EUR	— EUR	— EUR	42 452 EUR	169,000 EUR	42 283 EUR